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Clinical PerspectiveWhat Is New?Although type 2 diabetes mellitus is associated with oxidative stress, this is the first large prospective study to confirm an independent association between cardiovascular mortality and oxidative DNA damage in this setting.What Are the Clinical Implications?There remains an unmet need to modulate oxidative damage and validate its utility to reduce mortality in adults with type 2 diabetes mellitus.

Introduction {#jah33293-sec-0009}
============

It is well established that increased production of reactive oxygen species and the failure of endogenous antioxidant defenses against them results in a state of oxidative stress in diabetes mellitus and oxidative damage that contributes directly to the development and progression of diabetic complications.[1](#jah33293-bib-0001){ref-type="ref"} One useful biomarker of oxidative DNA damage is 8‐oxo‐2′‐deoxyguanosine (8‐oxo‐2′‐dG), an oxidized derivative of deoxyguanosine and one of the most abundant oxidative products of cellular DNA.[2](#jah33293-bib-0002){ref-type="ref"}, [3](#jah33293-bib-0003){ref-type="ref"} Urinary 8‐oxo‐2′‐dG has been independently associated with cardiovascular disease (CVD) in population cohorts[4](#jah33293-bib-0004){ref-type="ref"}, [5](#jah33293-bib-0005){ref-type="ref"}, [6](#jah33293-bib-0006){ref-type="ref"} and long‐term survival in patients with advanced CKD,[7](#jah33293-bib-0007){ref-type="ref"} heart failure (HF),[8](#jah33293-bib-0008){ref-type="ref"}, [9](#jah33293-bib-0009){ref-type="ref"} or cancer.[2](#jah33293-bib-0002){ref-type="ref"}, [3](#jah33293-bib-0003){ref-type="ref"} Yet, despite the recognized role of oxidative stress in diabetic complications, previous studies reported that spot urinary levels of 8‐oxo‐2′‐dG at diagnosis were not associated with subsequent mortality in Danish patients with type 2 diabetes mellitus.[10](#jah33293-bib-0010){ref-type="ref"}, [11](#jah33293-bib-0011){ref-type="ref"} This surprising finding may reflect the challenges of quantitative urinalysis in patients with type 2 diabetes mellitus in the community, especially when patients are poorly controlled (with polyuria and hyperfiltration) or have renal disease. To minimize these challenges, 8‐oxo‐2′‐dG can also be measured in stored plasma samples, although as a renally cleared metabolite, adjustment must be made for the simultaneous estimated glomerular filtration rate (eGFR).

In the present study, we explore the association between levels of circulating 8‐oxo‐2′‐dG and key adverse outcomes (death and cardiovascular events) in a nested case‐cohort study of adults with type 2 diabetes mellitus who participated in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial[12](#jah33293-bib-0012){ref-type="ref"}, [13](#jah33293-bib-0013){ref-type="ref"}, [14](#jah33293-bib-0014){ref-type="ref"} (<http://ClinicalTrials.gov> number NCT00145925).

Methods {#jah33293-sec-0010}
=======

Study Sample {#jah33293-sec-0011}
------------

The ADVANCE trial has been described in detail previously.[12](#jah33293-bib-0012){ref-type="ref"}, [13](#jah33293-bib-0013){ref-type="ref"}, [14](#jah33293-bib-0014){ref-type="ref"} High‐risk patients with type 2 diabetes mellitus were recruited from 20 countries in Asia, Australasia, Canada, and Europe. Participants were also required to be 55 years or older and have a history of CVD or ≥1 additional cardiovascular risk factor. The study included 2 randomized comparisons: a double‐blind assessment of the efficacy of a fixed combination of perindopril and indapamide (2/0.625 mg for 3 months increasing, if tolerated, to 4/1.25 mg) versus placebo, and an open‐label evaluation of an intensive glucose‐lowering regimen using modified release gliclazide, with a target glycated hemoglobin of ≤6.5%, versus standard guideline‐based glycemic control. A total of 11 140 participants were randomized and the median duration of follow‐up was 5 years. Approval for the trial was obtained from each center\'s institutional review board, and all participants provided written and informed consent.

Nonfasting blood samples were taken at baseline, anticoagulated with EDTA and stored centrally at −80°C for a median of 7.8 years before analyses. Stored plasma samples were available from all countries involved in ADVANCE, except China and India, giving a total base population of 7376 patients. A case‐cohort study population was constructed from a random sample of 3500 individuals, taken from these 7376 participants, plus all additional individuals who had a CVD event or a microvascular complication or died during follow‐up (n=697).

Baseline data included demographic and clinical information, including age at diagnosis, presence and severity of diabetic complications, antidiabetic therapy, and other regular medications. Weight, height, urinary albumin/creatinine ratio, serum creatinine, fasting lipid levels, and glycated hemoglobin were also measured at baseline. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation.[15](#jah33293-bib-0015){ref-type="ref"} Levels of baseline high‐sensitivity cardiac troponin T, NT‐proBNP (N‐terminal pro--brain natriuretic peptide), and high sensitivity C‐reactive protein were also measured on stored samples.[16](#jah33293-bib-0016){ref-type="ref"}, [17](#jah33293-bib-0017){ref-type="ref"}, [18](#jah33293-bib-0018){ref-type="ref"} Plasma 8‐oxo‐2′‐dG was measured by ELISA (StressMarq Biosciences Inc). The data and study materials will not be made available to other researchers for purposes of reproducing the results or replicating this analysis.

Study End Points {#jah33293-sec-0012}
----------------

The 4 primary study end points were all‐cause death, CVD death, non--CVD death, and major macrovascular events (cardiovascular death, nonfatal myocardial infarction \[MI\], or nonfatal stroke). Secondary outcomes were nonfatal MI, stroke, and admission to hospital for HF. All possible primary outcomes and deaths (cardiovascular and otherwise) were reviewed by an end point adjudication committee (comprising cardiologists, neurologists, endocrinologists, nephrologists, and ophthalmologists) whose members were blinded to randomized treatment assignments. Cardiovascular death was defined as any death in which the proximate or the underlying cause of death was caused by a disease of the circulatory system (*International Classification of Diseases, Tenth Revision* \[*ICD*‐*10*\], codes of I10--I14, I20--I25, I26, I27.9, I28, I50--I52, I60--I67, I69, I70--I79, I80--I89) or a sudden death (*ICD‐10* codes of R96.0, R96.1, I46.1, R98). Using the supporting documents, the committee either confirmed or refuted the initial diagnosis reported by the site investigators using standardized definitions. If the initial diagnosis made by the site investigator was refuted, an alternative diagnosis was provided.[19](#jah33293-bib-0019){ref-type="ref"}

Statistical Analyses {#jah33293-sec-0013}
--------------------

Baseline characteristics were summarized by ordinal categories defined by the thirds of 8‐oxo‐2′‐dG. Tests for linear trend were performed, across the thirds of each biomarker, to identify possible covariates associated with 8‐oxo‐2′‐dG using linear regression. Hazard ratios for log‐linear effects of 8‐oxo‐2′‐dG levels on each of the 3 studied outcomes were obtained from weighted Cox regression models for case‐cohort analyses.[18](#jah33293-bib-0018){ref-type="ref"} Nonfatal outcomes were analyzed using a Fine and Gray competing risk model, treating death from any cause as the competing event.[20](#jah33293-bib-0020){ref-type="ref"} Results were expressed per unit SD of 8‐oxo‐2′‐dG (3.5 ng/mL). Four models with different sets of potential confounding variables were fitted for each of the biomarker/outcome combinations: model 1 with age, sex, and randomized treatment; model 2 with, additionally, eGFR; model 3 with, additionally, albumin to creatinine ratio, duration of diabetes mellitus, current smoking, systolic blood pressure, body mass index, glycated hemoglobin, plasma glucose, total and high‐density lipoprotein cholesterol, triglycerides, and history of macrovascular complications; and model 4 with, additionally, high‐sensitivity C‐reactive protein, troponin, and NT‐proBNP. Analyses were also performed stratified by predefined characteristics at baseline: age (\>67 years versus ≤67 years), sex, a history of macrovascular complications, a history of microvascular complications, eGFR \< or ≥60 mL/min per 1.73 m^2^, and glycated hemoglobin \< or ≥7%, adjusted for the variables described in model 3.

Model 3 was used for the primary analysis. Cumulative survival plots were produced from the random subcohort, adjusting as in model 3. Log‐likelihood ratio tests were conducted to test the nonlinearity effect of 8‐oxo‐2′‐dG level on outcomes by comparing a model with categorical biomarkers and a model with continuous biomarkers. We tested the proportional hazards assumption by adding an interaction between the exposure and time. All analyses were performed using SAS software and a *P* value of \<0.05 was considered to confer statistical significance.

Results {#jah33293-sec-0014}
=======

Of the 4197 participants in the case‐cohort study, blood samples from 431 (10%) were missing or unsuitable for analysis. The remaining 3766 patients in this cohort had a mean age of 66.9 years and a mean duration of diabetes mellitus of 7.9 years (Table [1](#jah33293-tbl-0001){ref-type="table"}); 92% were white. A total of 1316 (34.9%) had a history of previous macrovascular disease.

###### 

Baseline Demographic, Clinical, and Laboratory Data Classified by Thirds of 8‐oxo‐2′‐dG

  Characteristic                                  First Third (n=1256)   Second Third (n=1254)   Third Third (n=1240)   Total (N=3766)     *P* for Trend
  ----------------------------------------------- ---------------------- ----------------------- ---------------------- ------------------ ---------------
  Male sex, No. (%)                               689/1256 (54.9)        801/1254 (63.9)         800/1256 (63.7)        2290/3766 (60.8)   \<0.0001
  Current smoking, No. (%)                        192/1256 (15.3)        188/1254 (15.0)         190/1256 (15.1)        570/3766 (15.1)    0.9113
  History of a macrovascular event, No. (%)       395/1256 (31.4)        433/1254 (34.5)         488/1256 (38.9)        1316/3766 (34.9)   0.0001
  Age, mean (SD), y                               66.65 (6.46)           66.95 (6.60)            67.13 (6.75)           66.91 (6.61)       0.0686
  Body mass index, mean (SD), kg/m^2^             29.32 (4.94)           30.09 (5.34)            30.68 (5.44)           30.03 (5.27)       \<0.0001
  Duration of diabetes mellitus, mean (SD), y     8.09 (6.33)            8.02 (6.51)             7.56 (6.50)            7.89 (6.45)        0.0389
  History of heart failure, No. (%)               47/1256 (3.7)          50/1254 (4.0)           74/1256 (5.9)          171/3766 (4.5)     0.01
  Moderate or vigorous activity, No. (%)          612/1256 (48.7)        625/1254 (49.8)         585/1256 (46.6)        1822/3766 (48.4)   0.2812
  Aspirin or other antiplatelet agent, No. (%)    576/1256 (45.9)        603/1254 (48.1)         673/1256 (53.6)        1852/3766 (49.2)   0.0001
  Statin or other lipid‐lowering agent, No. (%)   528/1256 (42.0)        549/1254 (43.8)         591/1256 (47.1)        1668/3766 (44.3)   0.0114
  β‐Blocker, No. (%)                              346/1256 (27.5)        384/1254 (30.6)         412/1256 (32.8)        1142/3766 (30.3)   0.0042
  ACEI or ARB, No. (%)                            724/1256 (57.6)        733/1254 (58.5)         777/1256 (61.9)        2234/3766 (59.3)   0.0314
  Systolic BP, mean (SD), mm Hg                   147.94 (21.56)         147.87 (21.03)          146.76 (22.25)         147.52 (21.62)     0.1712
  Diastolic BP, mean (SD), mm Hg                  81.89 (10.95)          82.03 (10.66)           80.82 (11.08)          81.58 (10.91)      0.0142
  Total cholesterol, mean (SD), mmol/L            5.16 (1.14)            5.11 (1.27)             5.13 (1.12)            5.13 (1.17)        0.5528
  HDL cholesterol, mean (SD), mmol/L              1.26 (0.34)            1.21 (0.32)             1.20 (0.33)            1.22 (0.33)        \<0.0001
  Triglycerides, mean (SD), mmol/L                1.79 (1.02)            1.90 (1.14)             2.18 (1.41)            1.96 (1.21)        \<0.0001
  Glycated hemoglobin, mean (SD), %               7.56 (1.52)            7.38 (1.44)             7.30 (1.32)            7.41 (1.43)        \<0.0001
  Urinary ACR, median (IQI), mg/mmol              48.21 (110.18)         52.80 (122.27)          65.60 (137.73)         55.55 (124.10)     0.0007
  Glucose, mean (SD), mmol/L                      8.66 (2.81)            8.44 (2.60)             8.31 (2.76)            8.47 (2.73)        0.0013
  eGFR, mean (SD), mL/min per 1.73 m^2^           75.53 (15.38)          72.24 (16.60)           66.63 (17.49)          71.47 (16.91)      \<0.0001
  hs‐CRP, median (IQI), mg/L                      3.37 (6.86)            3.58 (7.08)             3.94 (6.76)            3.63 (6.91)        0.0393
  hs‐cTNT, median (IQI), pg/mL                    7.47 (19.41)           8.61 (11.66)            11.06 (25.26)          9.04 (19.64)       \<0.0001
  NT‐proBNP, median (IQI), pg/mL                  190.22 (396.45)        220.75 (532.26)         381.15 (1404.1)        264.09 (900.59)    \<0.0001

8‐oxo‐2′‐dG indicates 8‐OH‐deoxyguanosine; ACEI, angiotensin‐converting enzyme inhibitor; ACR, albumin creatinine ratio; ARB, angiotensin receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; hs‐CRP, high‐sensitivity C‐reactive protein; hs‐cTNT, high‐sensitivity cardiac troponin T; IQI, interquartile interval; NT‐proBNP, N‐terminal pro--brain natriuretic peptide.

At baseline, circulating levels of 8‐oxo‐2′‐dG were highly correlated with eGFR (*r* ^2^=−0.24, *P*\<0.001), consistent with its primary route of excretion by the kidney. After adjusting for eGFR, 8‐oxo‐2′‐dG remained higher in participants with cardiac risk factors, including male sex, poor glycemic control, obesity, current smoking, atherogenic dyslipidemia, elevated systolic blood pressure, a prolonged duration of diabetes mellitus, and higher urinary albumin/creatinine ratio at baseline. Circulating levels of the cardiac marker NT‐proBNP were also higher in participants with the highest levels of 8‐oxo‐2′‐dG at baseline, even after adjusting for renal clearance of both substrates (*r* ^2^=0.26).

During a median of 5 years of follow‐up, 695 (18.4%) participants in this enriched cohort died (including 354 deaths from CVD). After adjusting for age, sex, and randomized treatment (Table [2](#jah33293-tbl-0002){ref-type="table"}) or after additionally adjusting for eGFR (model 2) and a wide range of other risk factors (model 3), individuals with higher levels of 8‐oxo‐2′‐dG were more likely to die (Figure [1](#jah33293-fig-0001){ref-type="fig"}A). Further adjustment for high‐sensitivity C‐reactive protein, troponin T, and NT‐proBNP further attenuated this association.

###### 

HRs (95% CIs) Per 1 SD (3.5 ng/mL) Higher 8‐oxo‐2′‐dG for Major and Composite End Points

                               HR (95% CI)         *P* Value
  ---------------------------- ------------------- -----------
  Model 1                                          
  All‐cause death              1.16 (1.07--1.25)   \<0.001
  Cardiovascular death         1.26 (1.14--1.38)   \<0.001
  Noncardiovascular death      1.05 (0.94--1.17)   0.42
  Major macrovascular events   1.11 (1.03--1.20)   0.006
  Total CVD                    1.15 (1.07--1.23)   \<0.001
  Model 2                                          
  All‐cause death              1.10 (1.02--1.19)   0.012
  Cardiovascular death         1.19 (1.08--1.31)   \<0.001
  Noncardiovascular death      1.01 (0.90--1.13)   0.87
  Major macrovascular events   1.06 (0.98--1.15)   0.16
  Total CVD                    1.09 (1.01--1.17)   0.027
  Model 3                                          
  All‐cause death              1.10 (1.01--1.20)   0.031
  Cardiovascular death         1.23 (1.10--1.37)   \<0.001
  Noncardiovascular death      0.98 (0.86--1.11)   0.705
  Major macrovascular events   1.08 (0.99--1.18)   0.080
  Total CVD                    1.11 (1.02--1.20)   0.014
  Model 4                                          
  All‐cause death              1.09 (0.99--1.19)   0.068
  Cardiovascular death         1.20 (1.07--1.34)   0.002
  Noncardiovascular death      0.98 (0.86--1.11)   0.714
  Major macrovascular events   1.06 (0.97--1.16)   0.177
  Total CVD                    1.09 (1.00--1.18)   0.041

Model 1: adjusted for age, sex, and randomized treatment groups. Model 2: model 1 plus estimated glomerular filtration rate (by Chronic Kidney Disease Epidemiology Collaboration equation). Model 3: model 2 plus duration of diabetes mellitus, current smoking, systolic blood pressure, body mass index, albumin to creatinine ratio, plasma glucose, glycated hemoglobin, total cholesterol, high‐density lipoprotein cholesterol, triglycerides, and history of macrovascular complications. Model 4: model 3 plus high‐sensitivity C‐reactive protein, troponin, and N‐terminal pro--brain natriuretic peptide. 8‐oxo‐2′‐dG indicates 8‐OH‐deoxyguanosine; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.

![Cumulative survival curves for all primary outcomes by quarter of 8‐oxo‐2′‐deoxyguanosine (8‐oxo‐2′‐dG), adjusted as in model 3 in Table [1](#jah33293-tbl-0001){ref-type="table"}. Blue, red, and green lines correspond, in this order, to increasing tertiles of 8‐ox‐dG. CVD indicates cardiovascular disease.](JAH3-7-e008226-g001){#jah33293-fig-0001}

The association between 8‐oxo‐2′‐dG and all‐cause mortality outcomes was driven by the independent association between 8‐oxo‐2′‐dG and CVD death, which remained significant after adjusting for other potentially confounding variables (Table [2](#jah33293-tbl-0002){ref-type="table"}; Figure [1](#jah33293-fig-0001){ref-type="fig"}B). Notably, no association was seen between 8‐oxo‐2′‐dG and non--CVD death (of which cancer was the major single cause) (Table [2](#jah33293-tbl-0002){ref-type="table"}; Figure [1](#jah33293-fig-0001){ref-type="fig"}C). There was no evidence of nonproportionality of hazards (*P*=0.70 for all‐cause death, 0.19 for cardiovascular death, 0.09 for noncardiovascular death).

The association between 8‐oxo‐2′‐dG and all‐cause and cardiovascular mortality outcomes was not significantly different across strata of age, sex, history of vascular disease, renal function, or glycemic control (Figure [2](#jah33293-fig-0002){ref-type="fig"}). There was no evidence of nonlinearity (*P*\>0.05) between 8‐oxo‐2′‐dG and mortality outcomes. There was no clear association between 8‐oxo‐2′‐dG and specific causes of documented CVD death (MI, stroke, or HF), although the power to perform this kind of subanalysis is limited because of the low number of fatal cardiovascular events.

![Hazard ratios (with 95% confidence intervals \[CIs\]) for all‐cause and cardiovascular death by predefined subgroups, adjusted as in model 3 in Table [1](#jah33293-tbl-0001){ref-type="table"}. eGFR indicates estimated glomerular filtration rate; HbA1c, glycated hemoglobin.](JAH3-7-e008226-g002){#jah33293-fig-0002}

During follow‐up, 680 (18.0%) participants experienced a major macrovascular event. Unlike survival and CVD mortality, the unadjusted association between 8‐oxo‐2′‐dG with major macrovascular events (MI, stroke, admission for HF) was eliminated after adjusting for only eGFR (Table [2](#jah33293-tbl-0002){ref-type="table"}; Figure [1](#jah33293-fig-0001){ref-type="fig"}D). Again, there was no evidence of nonproportionality of hazards (*P*=0.77 for major macrovascular events). 8‐Oxo‐2′‐dG was also not significantly associated with either nonfatal MI, nonfatal stroke, or hospitalization for HF, after adjusting for other risk factors (Table [3](#jah33293-tbl-0003){ref-type="table"}).

###### 

HRs (95% CIs) Per 1 SD (3.5 ng/mL) Higher 8‐oxo‐2′‐dG for Fatal and Nonfatal Individual Cardiovascular End Points

                          Fatal Events        Nonfatal Events[a](#jah33293-note-0006){ref-type="fn"}                       
  ----------------------- ------------------- -------------------------------------------------------- ------------------- ---------
  Model 1                                                                                                                  
  Myocardial infarction   1.25 (0.98--1.60)   0.070                                                    1.02 (0.89--1.17)   0.771
  Stroke                  1.17 (0.95--1.45)   0.136                                                    0.97 (0.83--1.13)   0.692
  Heart failure           1.43 (1.17--1.74)   \<0.001                                                  1.23 (1.10--1.37)   \<0.001
  Model 2                                                                                                                  
  Myocardial infarction   1.20 (0.92--1.56)   0.170                                                    0.96 (0.83--1.10)   0.567
  Stroke                  1.12 (0.91--1.37)   0.288                                                    0.92 (0.79--1.08)   0.325
  Heart failure           1.35 (1.09--1.68)   0.006                                                    1.11 (0.98--1.26)   0.103
  Model 3                                                                                                                  
  Myocardial infarction   1.30 (0.96--1.76)   0.091                                                    0.95 (0.81--1.11)   0.497
  Stroke                  1.21 (0.99--1.48)   0.065                                                    0.97 (0.82--1.16)   0.761
  Heart failure           1.35 (0.97--1.88)   0.076                                                    1.12 (0.97--1.30)   0.132
  Model 4                                                                                                                  
  Myocardial infarction   1.31 (0.97--1.77)   0.081                                                    0.93 (0.80--1.10)   0.407
  Stroke                  1.20 (0.98--1.46)   0.081                                                    0.95 (0.80--1.13)   0.534
  Heart failure           1.28 (0.87--1.86)   0.208                                                    1.10 (0.95--1.27)   0.207

Model 1: adjusted for age, sex, and randomized treatment groups. Model 2: model 1 plus estimated glomerular filtration rate (by Chronic Kidney Disease Epidemiology Collaboration equation). Model 3: model 2 plus duration of diabetes mellitus, current smoking, systolic blood pressure, body mass index, albumin to creatinine ratio, plasma glucose, glycated hemoglobin, total cholesterol, high‐density lipoprotein cholesterol, triglycerides, and history of macrovascular complications. Model 4: model 3 plus high‐sensitivity C‐reactive protein, troponin, and N‐terminal pro--brain natriuretic peptide. 8‐oxo‐2′‐dG indicates 8‐OH‐deoxyguanosine; CI, confidence interval; HR, hazard ratio.

Allowing for the competing risk of death.

Discussion {#jah33293-sec-0015}
==========

Oxidative stress is recognized as a clear antecedent of end‐organ dysfunction and disease, and diabetes mellitus is associated with increased levels of oxidative stress.[1](#jah33293-bib-0001){ref-type="ref"} In this study, we demonstrate that 8‐oxo‐2′‐dG, a marker of oxidative damage, is independently associated with all‐cause mortality and cardiovascular mortality in adults with longstanding type 2 diabetes mellitus who participated in the ADVANCE trial. This finding is consistent with smaller observational studies linking survival of patients with diabetes mellitus to other markers of oxidative stress, including oxidized RNA,[10](#jah33293-bib-0010){ref-type="ref"}, [11](#jah33293-bib-0011){ref-type="ref"} derivatives of reactive oxygen metabolite,[19](#jah33293-bib-0019){ref-type="ref"} advanced autoxidation products,[2](#jah33293-bib-0002){ref-type="ref"}, [20](#jah33293-bib-0020){ref-type="ref"} and F‐isoprostanes.[2](#jah33293-bib-0002){ref-type="ref"}, [20](#jah33293-bib-0020){ref-type="ref"} However, this is the first large prospective study to confirm an independent association between mortality and 8‐oxo‐2′‐dG in type 2 diabetes mellitus.

Because of the inherent reactivity of reactive oxygen species, oxidative stress is most easily evaluated by quantitation of oxidative modifications, of which 8‐oxo‐2′‐dG is a highly relevant, stable, and easily measured by‐product. Although widely considered a marker of oxidative DNA damage, 8‐oxo‐2′‐dG may also partly reflect the rate of its liberation via DNA repair mechanisms[1](#jah33293-bib-0001){ref-type="ref"}, [21](#jah33293-bib-0021){ref-type="ref"}, [22](#jah33293-bib-0022){ref-type="ref"} and oxidatively damaged 2′‐deoxyguanosine from the nucleotide pool. 8‐Oxo‐2′‐dG is also clearly associated with kidney function. In most previous studies, the failure to adjust for renal clearance clearly undermines conclusions based on free 8‐oxo‐2′‐dG levels in the circulation or urine.[21](#jah33293-bib-0021){ref-type="ref"} Certainly, in our study, some of the association between plasma 8‐oxo‐2′‐dG levels and mortality was explained by the confounding effect of renal impairment. Although we have specifically adjusted for eGFR in this analysis (model 2), and the association between 8‐oxo‐2′‐dG and mortality remained significant after this adjustment, it is possible we still may have underestimated the role of kidney disease in outcomes, as kidney disease itself may be considered a cause of oxidative stress. Consistent with this hypothesis, the ratio of plasma 8‐oxo‐2′‐dG to eGFR rose as eGFR levels fell in participants in this study.

Recent studies have suggested that 8‐oxo‐2′‐dG may be associated with both the presence of HF and its severity and prognosis.[6](#jah33293-bib-0006){ref-type="ref"}, [8](#jah33293-bib-0008){ref-type="ref"} Although few patients had an overt history of HF in our ADVANCE cohort, an association between 8‐oxo‐2′‐dG and cardiac function has also been reported in patients with hypertension without overt heart disease.[23](#jah33293-bib-0023){ref-type="ref"} Consistent with this hypothesis, plasma levels of NT‐proBNP were independently associated with 8‐oxo‐2′‐dG in our cohort, suggesting that 8‐oxo‐2′‐dG may also be a marker of oxidative injury in the heart and occult cardiac dysfunction in our cohort, therein partly explaining the association of 8‐oxo‐2′‐dG and cardiovascular mortality. Indeed, it has been suggested that 8‐oxo‐2′‐dG and NT‐proBNP may be markers of the same process, as oxidative damage may be causally related to cardiac dysfunction. However, even after adjusting for NT‐proBNP and TNT in our multivariate models, the association between 8‐oxo‐2′‐dG and cardiovascular mortality remained significant (*P*=0.01), suggesting that the link is more complex.

Although 8‐oxo‐2′‐dG was associated with major macrovascular events after adjusting for age and sex, this association disappeared after adjusting for eGFR. As oxidative stress is a key mechanism by which these risk factors may be linked to mortality outcomes, such adjustment may not reflect the true role of oxidative damage in the development and progression of CVD. Despite the clear association of 8‐oxo‐2′‐dG with the risk of CVD death, there was no such association with the combination of fatal and nonfatal CVD (major macrovascular events). This is despite the greater power for the latter, owing to the larger number of events. This unusual pattern was also observed in the recent EMPA‐REG outcomes trial[24](#jah33293-bib-0024){ref-type="ref"} where CVD death was reduced without a reduction in nonfatal CVD events, and potentially points to the different pathogenic forces in total CVD events when compared with CVD death, with a potentially important role for oxidative stress in the latter. Notably, similar to EMPA‐REG outcomes, both death from HF and hospitalization for HF were associated with 8‐oxo‐2′‐dG. However, this association was attenuated after adjusting for other risk factors, although the small number of HF events means there is a low power to explore this outcome in any detail.

Study Strengths and Limitations {#jah33293-sec-0016}
-------------------------------

The strengths of this study include the large cohort of well‐characterized patients, with few dropouts (only 17 of 11 140 in the original study), outcome verification by an independent review committee, and the high level of diabetes mellitus care, typical of a clinical trial. A limitation is that oxidative stress was quantified by means of a single measure, which is clearly inadequate for a dynamic process. We also used an ELISA to assess 8‐oxo‐2′‐dG in plasma samples, as conventional chromatographic methods do not have the sensitivity to measure plasma levels. Although the circulating levels of 8‐oxo‐2′‐dG detailed in this study are similar to those reported in cross‐sectional studies using ELISA‐based assays in patients with diabetes mellitus[25](#jah33293-bib-0025){ref-type="ref"}, [26](#jah33293-bib-0026){ref-type="ref"}, [27](#jah33293-bib-0027){ref-type="ref"} and other settings,[28](#jah33293-bib-0028){ref-type="ref"}, [29](#jah33293-bib-0029){ref-type="ref"}, [30](#jah33293-bib-0030){ref-type="ref"}, [31](#jah33293-bib-0031){ref-type="ref"}, [32](#jah33293-bib-0032){ref-type="ref"} it is understood that ELISA overestimates 8‐oxo‐2′‐dG when compared with high‐sensitivity mass spectroscopy.[33](#jah33293-bib-0033){ref-type="ref"} This is partly because of the former method including DNA fragments containing 8‐oxo‐2′‐dG, in addition to free 8‐oxo‐2′‐dG, as well as the presence of interfering compounds in plasma. Nonetheless, the clear correlation of 8‐oxo‐2′‐dG with mortality is consistent with prior data on other markers of oxidative stress.

Finally, observational studies only demonstrate association and not causality. Although there is a strong scientific rationale, the mechanics (causality) behind these observations are beyond the scope of the current investigation. We have undertaken detailed analyses to control for possible confounders, eg, in multivariate regression, and competing risk analysis. We have clearly shown that after adjusting for conventional risk factors associated with CVD death, an independent association between 8‐oxo‐2′‐dG was maintained. This suggests that 8‐oxo‐2′‐dG is not just an epiphenomenon. However, it is not possible to account for unmeasured confounders, such as microbiome and diet composition, mental health, or exposure to atmospheric pollution, all of which may influence markers of oxidative stress and CVD mortality.

Conclusions {#jah33293-sec-0017}
===========

8‐Oxo‐2′‐dG is independently associated with CVD death and all‐cause mortality in patients with type 2 diabetes mellitus, consistent with the role of oxidative damage in the development and progression of cardiovascular decompensation in diabetes mellitus. This observation supports the call for better‐targeted antioxidant therapies[34](#jah33293-bib-0034){ref-type="ref"} and well‐designed appropriately powered human studies, especially in those with elevated CVD risk, in whom oxidative stress is usually particularly high and remains untreated.
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**Appendix S1.** ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) Collaborative Group (centers and names).
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Click here for additional data file.

[^1]: A complete list of the ADVANCE Collaborative Group is provided in Appendix [S1](#jah33293-sup-0001){ref-type="supplementary-material"}.
